Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Number of holders
-
21
-
Total 13F principal, excl. options
-
301,166,967
-
Principal change
-
-21,587,333
-
Total reported value, excl. options
-
$274,825,761
-
Value change
-
-$26,924,802
-
Number of buys
-
9
-
Number of sells
-
-9
-
Price
-
$0.9119
Significant Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2022
28 filings reported holding 89422GAA5 - TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2022.
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 has 21 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $301,166,967 of principal
.
Largest 10 bondholders include CAPSTONE INVESTMENT ADVISORS, LLC ($48,043,000 of principal), D. E. Shaw & Co., Inc. ($38,189,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($37,900,000 of principal), LAZARD ASSET MANAGEMENT LLC ($31,500,000 of principal), BRAIDWELL LP ($31,350,000 of principal), Polar Asset Management Partners Inc. ($30,000,000 of principal), CITIGROUP INC ($15,000,000 of principal), AVIVA PLC ($15,000,000 of principal), HIGHBRIDGE CAPITAL MANAGEMENT LLC ($10,082,000 of principal), and READYSTATE ASSET MANAGEMENT LP ($9,000,000 of principal).
This table shows the top 21 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.